Company: ALS Therapy Development Institute
Drug Type: Protein Biologic
Mechanism Type: Immunomodulation
Mechanism: TDI-846 (blocking antibody to CD40L) is designed to modulate the immune response associated with disease progression in ALS.
U.S. Status for ALS: Preclinical
 From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Lincecum JM et al. Nat Genet. 2010 May;42(5):392-9.
 AntiCD40L (TDI28). ALS Therapy Development Institute, 2016. Accessed 9 Mar 2016 from http://www.alstdi.org/als-research/als-topics/anticd40l/.
Last updated March 9th, 2016